Mega Genomics (HKSE:06667) Cash, Cash Equivalents, Marketable Securities : HK$547.9 Mil (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Mega Genomics Cash, Cash Equivalents, Marketable Securities?

Mega Genomics's quarterly cash, cash equivalents, marketable securities increased from Jun. 2023 (HK$471.05 Mil) to Dec. 2023 (HK$566.89 Mil) but then stayed the same from Dec. 2023 (HK$566.89 Mil) to Jun. 2024 (HK$547.89 Mil).

Mega Genomics's annual cash, cash equivalents, marketable securities increased from Dec. 2021 (HK$292.77 Mil) to Dec. 2022 (HK$446.50 Mil) and increased from Dec. 2022 (HK$446.50 Mil) to Dec. 2023 (HK$566.89 Mil).

Mega Genomics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Mega Genomics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Genomics Cash, Cash Equivalents, Marketable Securities Chart

Mega Genomics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

58.58

247.10

292.77

446.50

566.89

Mega Genomics Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial				440.24	446.50	471.05	566.89	547.89

Mega Genomics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Mega Genomics (HKSE:06667) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Mega Genomics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Mega Genomics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Mega Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mega Genomics Ltd (HKSE:06667) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

North Garden Road, 401 Health Work, Haidian District, Beijing, CHN

Website

https://www.megagenomics.cn

Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening, and infectious disease diagnosis, to meet consumers growing preventive medical needs. It generates a majority of its revenue from consumer genetic testing services.

Executives

Dongyin Industrial (shenzhen) Co., Ltd.	2106 Person having a security interest in shares
Dongyin (tianjin) Enterprise Management Consulting Co., Ltd.	2106 Person having a security interest in shares
Dongfu Hetong (tianjin) Equity Investment Fund Partnership Enterprise (limited Partnership)	2106 Person having a security interest in shares
Yurong Technology Limited	2101 Beneficial owner
Dongfu (beijing) Investment Management Co., Ltd.	2106 Person having a security interest in shares
Dong Yin Development (holdings) Limited	2106 Person having a security interest in shares
China Orient Asset Management Co., Ltd.	2106 Person having a security interest in shares
Beijing Dongfu Huitong Investment Management Center (limited Partnership)	2106 Person having a security interest in shares
Guo Meiling	2101 Beneficial owner
Yu Rong	2501 Other
Lin Lin	2101 Beneficial owner
Infinite Galaxy Health Limited	2101 Beneficial owner
Bei Jing He He Heng Ye Ke Ji You Xian Gong Si	2201 Interest of corporation controlled by you
Tian Jin Shi Ji Yu Neng Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Bei Jing Shi Ji Yu Neng Ke Ji You Xian Gong Si	2501 Other

Mega Genomics Headlines

No Headlines